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Abstract
Background: Governments, funding bodies, institutions, and publishers have developed a number of strategies to
encourage researchers to facilitate access to datasets. The rationale behind this approach is that this will bring a
number of benefits and enable advances in healthcare and medicine by allowing the maximum returns from the
investment in research, as well as reducing waste and promoting transparency. As this approach gains momentum,
these data-sharing practices have implications for many kinds of research as they become standard practice across
the world.
Main text: The governance frameworks that have been developed to support biomedical research are not well
equipped to deal with the complexities of international data sharing. This system is nationally based and is
dependent upon expert committees for oversight and compliance, which has often led to piece-meal decision-
making. This system tends to perpetuate inequalities by obscuring the contributions and the important role of
different data providers along the data stream, whether they be low- or middle-income country researchers,
patients, research participants, groups, or communities. As research and data-sharing activities are largely publicly
funded, there is a strong moral argument for including the people who provide the data in decision-making and to
develop governance systems for their continued participation.
Conclusions: We recommend that governance of science becomes more transparent, representative, and responsive to
the voices of many constituencies by conducting public consultations about data-sharing addressing issues of access
and use; including all data providers in decision-making about the use and sharing of data along the whole of the data
stream; and using digital technologies to encourage accessibility, transparency, and accountability. We anticipate that this
approach could enhance the legitimacy of the research process, generate insights that may otherwise be overlooked or
ignored, and help to bring valuable perspectives into the decision-making around international data sharing.
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Modern biomedical research has been accelerated by
advances in digital technologies [1], enabling interdis-
ciplinary collaborations to collect, analyze and share
different kinds of data across the globe. To facilitate
data sharing, governments, funding bodies, institutions,
and publishers have developed data infrastructures,
policies, and incentives. Global data sharing is antici-
pated by many commentators to boost progress in
health and medicine, reduce research waste, increase
research value, and promote research transparency [2].
While most research data are generated by researchers,
digital innovation has enabled patients and citizens to
be involved in data collection and creation through the
use of smart phones and devices, and involvement in
citizen-science projects. The scope of data considered
to be health-related has also expanded to include
demographic, administrative, socio-economic, medical,
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and behavioral measures as well as genomics and
multi-omics data which can be derived from a number
of different sources.
While data sharing is strongly encouraged, concerns
exist that the existing governance frameworks of data
sharing are inappropriate to cope with the size, scope,
complexity, and scale of data sharing that is required
in modern health research [3–5]. Furthermore, we
argue that these frameworks tend to perpetuate, or
even exacerbate, many of the current inequalities in
research and health by obscuring the important role of
those who donate data, whether they be low- or
middle-income country researchers, patients, research
participants, groups, or communities [6]. This paper
will discuss some of the inadequacies of the existing
governance systems for research and suggest an ap-
proach to bring the voices of data contributors into
decision-making around data sharing.
Flaws of the current data-sharing governance
frameworks
Current data-sharing governance frameworks are not
attuned to the needs of multi-institutional or multi-
jurisdictional health research [3]. In most countries,
governance systems primarily are tied to territorial
jurisdictions; these systems were originally developed
to protect personal data within a single jurisdiction.
Efforts to combine or sequentially apply territorial
governance structures across borders may lead to un-
due complexity and bureaucratic regulatory thickets
resulting in inefficient data flows characterized by
delays in the research progress [7, 8]. Applying local
or territorial governance to broader areas overloads
the structures to a point where they are either in-
appropriate or lose their moral legitimacy by failing
to reflect the concerns, interests, and values of all of
the data contributors involved. This means that the
movement of data becomes a series of contractual
transactions or transfers in which it is very difficult to
know if data have been used according to the wishes
of data donors and curators further upstream in the
research process as the data move through global
networks.
Such a system also has the tendency to perpetuate
inequalities by obscuring the contributions of different
stakeholders along the data stream. This is particularly
problematic if it creates a proportionately greater dis-
advantage for people in resource-poor countries to
contribute to, be recognized for, and benefit from
science. It also does not recognize the connectivity be-
tween data providers [9], and may contribute to mut-
ing the voices of the data contributors as data move
progressively away from them. This lack of connection
between the data providers and those who use the data
can lead to potentially unjust outcomes that are not in
accordance with the expectations of those who are
providing data. Ultimately most data on individuals
requires consent to be obtained. If data are shared in
ways that appear contrary to the interests of the sub-
jects and donors of that data, this could lead to a loss
of trust in the research process and to people with-
holding consent and refusing to participate in further
research.
Institutional Review Boards [10] or Research Ethics
Committees [7] are the key governance bodies for
research overseeing the recruitment of participants
into the initial study, when data are generated. These
committees often are based locally and must make de-
cisions on behalf of participants domiciled within their
jurisdictions. In multi-institutional research, several
such committees perform their reviews in a succeeding
manner with the same goal of protecting the interests
of local participants, researchers, and institutions. This
can lead to differences in decision-making, not only
just between national committees, but also committees
within the same jurisdiction. Although there may be
patients and participants sitting on these committees
as representatives, decisions are made on behalf of
research participants by experts. The end result of this
piece-meal decision-making is that it may not be in
accordance with what individuals, groups, and commu-
nities want in terms of international data sharing [11].
While in many regions of the world such as sub-
Saharan Africa, mechanisms have been developed to
engage communities and obtain their consent before
research implementation [12, 13], such mechanisms
are not broadly adopted in western countries or other
countries with advanced biomedical research. Gener-
ally, community perspectives and formal public consul-
tations are not requirements in the deliberations and
decision-making regarding international data sharing.
Proposed new data-sharing governance
frameworks
Recently, platforms have been developed to support
the use of scientific data and to address some of the
challenges described above. Examples include the
newly proposed European Open Science Cloud [14],
the Global Alliance for Genomics and Health [15, 16],
the Database of Genotypes and Phenotypes (dbGaP)
[17], and the European Genome-phenome Archive
[18]. Within these managed access platforms, new
forms of governance are applied that sit alongside the
traditional oversight bodies of expert ethics commit-
tees. For instance, Data Access Committees have
become a standard oversight body for the approval of
access to research platform by researchers [19], with
some committees undertaking responsibility for a
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number of studies such as in the case of METADAC
[20]. To facilitate access to data, new governance
mechanisms such as ‘pop-up’ governance [21] have
been developed by research consortia. In such projects,
data access committees are established at a consortium
level and provide greater control for the researchers
who have collected the data, and, potentially, for the
participants who donate their data as well.
Many of these initiatives have largely been instigated
by researchers and funding bodies in high-resourced
countries, supported by foundational documents such
as the Fort Lauderdale Agreement of 2003 [22] and the
Toronto Statement of 2009 [23]. These governance sys-
tems have varying levels of participation from different
stakeholders, but overall, the data-sharing agenda
usually is formulated by a handful of stakeholders such
as funding agencies and research organizations, in
which regional or national regulatory frameworks have
been considered on a case-by-case basis. Generally, dis-
cussions on biomedical data sharing are conducted
from the perspective of those leading the development
of the current global infrastructure for health science
research, namely, academia, pharmaceutical companies,
clinical health IT systems, funders, insurers, and
policy-makers. Although all of them would state that
they are fundamentally concerned with health and the
furtherance of the public good, the vested interests of
this infrastructure (i.e., academic achievement, the
profit motive, international political competition) may
not align with the solutions identified above [24]. This
can not only lead to inequalities between researchers in
low- and high-resourced countries [25], but also an
agenda that does not necessarily embody the concerns
of research participants.
To some extent, patient organizations have undertaken
similar initiatives to create opportunities for both data
generation and sharing. Examples are enabling research
participants or patients to directly upload health informa-
tion or share genetic variants [26], or requiring collaborat-
ing investigators to share data as a condition of receiving
registry data or biobank samples. While this has become
more of the norm in terms of rare diseases, in other areas,
this is not necessarily the case. The more commonplace
situation for global infrastructure is that the people from
whom the data originate, i.e., the research participant, the
patient receiving treatment, the family member providing
blood, or the community volunteering information, are
not routinely provided with the opportunity for involve-
ment in the design and management of data-storage deci-
sions, or sharing practices [27, 28].
An inclusive and global approach
There is a pressing and growing need for a data-sharing
governance framework that is inclusive, global, and
transparent. Such a framework should enable the in-
volvement of all of those who have contributed the data
and who have an interest in the health research carried
out, while still accounting for variations in those inter-
ests across different stakeholders. Further, it would
stretch beyond national borders, include the lens of
responsible data use and accountability, and enable
democracy in a pluralistic global community. The key
challenge becomes, then, how to reform the national
data-sharing governance structure and to scale it up to
a global level to produce a structure that is attentive to
stakeholders from all of the research constituencies
(research users, public and participants, industry,
policy-makers, and researchers themselves) from all of
the territories that those stakeholders inhabit (not just
the western research paradigm) [29]. Such a perspective
will encourage paradigm shifts in the way we manage
and disseminate data, even in the face of entrenched
systems [30]. To achieve this, we need to orient the dis-
cussions about priorities around the individuals from
whom the data are obtained and to include a broader
range of constituencies in planning and oversight.
Currently, generation and access criteria for data,
samples and other materials vary considerably between
national and international repositories in terms of per-
mission levels, review bodies and policy requirements
[31]. Ensuring global equity in the value of large scale
data-sharing will require systems that are used in all
countries and recognized by all users and producers of
data. The same advances in technology that present the
challenges described above can also be part of the solu-
tion, enabling a better representation of the various
values and cultures of the data providers and the com-
munities they represent. With regards to a technical
infrastructure, developing a global governance system
that is appropriate for sharing and enabling the appro-
priate flow of data will require interoperable systems
across all countries that are secure, transparent and
accountable [32], and accessibility by all contributors,
producers, and users of data [32, 33]. While individual
systems employed by discrete projects need not be uni-
form, central or common, they should be harmonized
so as to be designed around a transparent set of fea-
tures that make them compatible with those used else-
where, and comprehendible to an external audience.
Such systems must enable local and regional and
socio-cultural decisions to be made with regard to
sharing that respect the participants, and still permit
the available data to be shared. Enabled by advances in
electronic communication, the basic governance
mechanisms that will allow this are in the process of
development. Examples are the ORCID identification
initiative, building a registry of unique researcher
identifiers that could be used as a passport for
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allowing access to datasets and legitimate uses of data
[34]; ‘Dynamic Consent’, an online interface that
enables ongoing communication between data volun-
teers (participants) and users (researchers), and allows
consent preferences to be modified over time [35]; and
ÉCOUTER, an online tool for engaging and analyzing
stakeholder perspectives [36, 37]. Widespread adop-
tion of these systems would promote integrity, ac-
countability, legitimacy, and trust.
Importantly, data-sharing governance structures
must include the general public in setting priorities
and determining how data are used. If we assume that
data sharing is a means to an end, and that end is to
benefit all communities equally, then the gold standard
of public consultation should be to begin in a place
that considers all communities in their own context.
This means avoiding hypothetical person-centered ap-
proaches that presume a universal ‘reasonable person’
standard: if we want to understand how data sharing
should occur in a particular country or region or how
research participants can or do contribute to data-
sharing planning, we need to do so empirically using a
collection of robust and recognized social science
approaches [6, 12].
In practice, we have a long way to go to achieving this
ambition, but it is a perspective that will provide a
strong framework for considering new options and
could be transformative in integrating the tensions be-
tween the collective and the individual. In some coun-
tries, recent initiatives by funders of healthcare
research to engage members of their public in decision-
making processes have been praised for helping to re-
direct research questions towards the needs of patients
[38]. It is now widely accepted that research questions
and research design benefit from public consultation,
and the same approach should apply to the design of
data-sharing mechanisms, particularly when drafting
data management plans and governance plans for data
infrastructure, rather than this being the sole responsi-
bility of researchers. Securing the involvement of both
scientific and participant data providers in the decision-
making of consortia and data infrastructure is another
mechanism to account for publicly funded research
activities and ensuring that these voices are heard.
Conclusion
Good practices for data sharing must evolve towards
an interoperable set of standards, permitting sharing
across borders. Good practices must also ensure that
all views are heard and taken into account when de-
fining these standards. The governance of science will
have to become more transparent, representative, and
responsive to the voices of many constituencies, with
all the prospects for discord, compromise, and delay
that this implies. We argue that as research and data-
sharing activities are largely publicly funded, there is
a strong moral argument for including the people
who provide the data in decision-making and to de-
velop governance systems to enable their continued
participation. We further argue creative engagement
of individual, familial, and community data volunteers
with all stakeholders across boundaries, whether dis-
ciplinary, institutional, or national, has the potential
to generate insights that may otherwise be overlooked
or ignored when global perspectives are less compre-
hensive. This creative engagement can also reduce
research waste [39, 40] by removing duplication and
avoiding avenues of exploration already known to be
dead ends. We also argue that appropriate data shar-
ing can, and does, permit significant advances in our
understanding of many complex health-related issues,
helping to address currently unmet health needs.
The question is whether we have the political will to
develop and facilitate these good data sharing prac-
tices. We have the technology that can enable us to do
this now, in system examples such as ORCID; ‘Dy-
namic Consent’; and ÉCOUTER. Funding agencies and
research organizations, which recognize the potential
efficiency gains from data sharing and are critical in
the formulation of the data-sharing agenda should re-
view and revise their data sharing policies to involve
participants [41].
When pursued from the perspective of the donors of
information, and structured for their benefit, collective
exploitation of data between stakeholders and across
communities will create the possibility of improving effi-
ciency and more importantly, of addressing inequalities.
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